|
1
|
Hoos A, Lewis JJ and Brennan MF: Soft
tissue sarcoma: prognostic factors and multimodal treatment.
Chirurg. 71:787–794. 2000.In German. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mack TM: Sarcomas and other malignancies
of soft tissue, retroperitoneum, peritoneum, pleura, heart,
mediastinum, and spleen. Cancer. 75(Suppl 1): 211–244. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dalal KM, Kattan MW, Antonescu CR, Brennan
MF and Singer S: Subtype specific prognostic nomogram for patients
with primary liposarcoma of the retroperitoneum, extremity, or
trunk. Ann Surg. 244:381–391. 2006.PubMed/NCBI
|
|
4
|
Kransdorf MJ: Malignant soft-tissue tumors
in a large referral population: distribution of diagnoses by age,
sex, and location. AJR Am J Roentgenol. 164:129–134. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stojadinovic A, Leung DH, Hoos A, Jaques
DP, Lewis JJ and Brennan MF: Analysis of the prognostic
significance of microscopic margins in 2,084 localized primary
adult soft tissue sarcomas. Ann Surg. 235:424–434. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kaushal A and Citrin D: The role of
radiation therapy in the management of sarcomas. Surg Clin North
Am. 88:629–646. viii2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Singer S, Demetri GD, Baldini EH and
Fletcher CD: Management of soft-tissue sarcomas: an overview and
update. Lancet Oncol. 1:75–85. 2000. View Article : Google Scholar
|
|
8
|
Collin C, Godbold J, Hajdu S and Brennan
M: Localized extremity soft tissue sarcoma: an analysis of factors
affecting survival. J Clin Oncol. 5:601–612. 1987.PubMed/NCBI
|
|
9
|
Pisters PW and Pollock RE: Staging and
prognostic factors in soft tissue sarcoma. Semin Radiat Oncol.
9:307–314. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gaynor JJ, Tan CC, Casper ES, Collin CF,
Friedrich C, Shiu M, Hajdu SI and Brennan MF: Refinement of
clinicopathologic staging for localized soft tissue sarcoma of the
extremity: a study of 423 adults. J Clin Oncol. 10:1317–1329.
1992.PubMed/NCBI
|
|
11
|
Pisters PW, Leung DH, Woodruff J, Shi W
and Brennan MF: Analysis of prognostic factors in 1,041 patients
with localized soft tissue sarcomas of the extremities. J Clin
Oncol. 14:1679–1689. 1996.PubMed/NCBI
|
|
12
|
Matsumoto S, Ahmed AR, Kawaguchi N, Manabe
J and Matsushita Y: Results of surgery for malignant fibrous
histiocytomas of soft tissue. Int J Clin Oncol. 8:104–109. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lewis JJ, Leung D, Heslin M, Woodruff JM
and Brennan MF: Association of local recurrence with subsequent
survival in extremity soft tissue sarcoma. J Clin Oncol.
15:646–652. 1997.PubMed/NCBI
|
|
14
|
Daigeler A, Zmarsly I, Hirsch T, Goertz O,
Steinau HU, Lehnhardt M and Harati K: Long-term outcome after local
recurrence of soft tissue sarcoma: a retrospective analysis of
factors predictive of survival in 135 patients with locally
recurrent soft tissue sarcoma. Br J Cancer. 110:1456–1464. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Spillane AJ, Fisher C and Thomas JM:
Myxoid liposarcoma – the frequency and the natural history of
nonpulmonary soft tissue metastases. Ann Surg Oncol. 6:389–394.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ghadimi MP, Al-Zaid T, Madewell J, Peng T,
Colombo C, Hoffman A, Creighton CJ, Zhang Y, Zhang A, Lazar AJ, et
al: Diagnosis, management, and outcome of patients with
dedifferentiated liposarcoma systemic metastasis. Ann Surg Oncol.
18:3762–3770. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hoffman A, Ghadimi MP, Demicco EG,
Creighton CJ, Torres K, Colombo C, Peng T, Lusby K, Ingram D,
Hornick JL, et al: Localized and metastatic myxoid/round cell
liposarcoma: clinical and molecular observations. Cancer.
119:1868–1877. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Billingsley KG, Lewis JJ, Leung DH, Casper
ES, Woodruff JM and Brennan MF: Multifactorial analysis of the
survival of patients with distant metastasis arising from primary
extremity sarcoma. Cancer. 85:389–395. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Billingsley KG, Burt ME, Jara E, Ginsberg
RJ, Woodruff JM, Leung DH and Brennan MF: Pulmonary metastases from
soft tissue sarcoma: analysis of patterns of diseases and
postmetastasis survival. Ann Surg. 229:602–610; discussion 610–612.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Van Glabbeke M, van Oosterom AT,
Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J,
Santoro A, Buesa J and Tursz T: Prognostic factors for the outcome
of chemotherapy in advanced soft tissue sarcoma: an analysis of
2,185 patients treated with anthracycline-containing first-line
regimens - a European Organization for Research and Treatment of
Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol.
17:150–157. 1999.PubMed/NCBI
|
|
21
|
Italiano A, Toulmonde M, Cioffi A, Penel
N, Isambert N, Bompas E, Duffaud F, Patrikidou A, Lortal B, Le
Cesne A, et al: Advanced well-differentiated/dedifferentiated
liposarcomas: role of chemotherapy and survival. Ann Oncol.
23:1601–1607. 2012. View Article : Google Scholar
|
|
22
|
Italiano A, Garbay D, Cioffi A, Maki RG
and Bui B: Advanced pleomorphic liposarcomas: clinical outcome and
impact of chemotherapy. Ann Oncol. 23:2205–2206. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jones RL, Fisher C, Al-Muderis O and
Judson IR: Differential sensitivity of liposarcoma subtypes to
chemotherapy. Eur J Cancer. 41:2853–2860. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Patel SR, Burgess MA, Plager C,
Papadopoulos NE, Linke KA and Benjamin RS: Myxoid liposarcoma.
Experience with chemotherapy. Cancer. 74:1265–1269. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brodowicz T, Schwameis E, Widder J, Amann
G, Wiltschke C, Dominkus M, Windhager R, Ritschl P, Pötter R, Kotz
R and Zielinski CC: Intensified adjuvant IFADIC chemotherapy for
adult soft tissue sarcoma: a prospective randomized feasibility
trial. Sarcoma. 4:151–160. 2000. View Article : Google Scholar
|
|
26
|
Frustaci S, Gherlinzoni F, De Paoli A,
Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti
G, Barbieri E, et al: Adjuvant chemotherapy for adult soft tissue
sarcomas of the extremities and girdles: results of the Italian
randomized cooperative trial. J Clin Oncol. 19:1238–1247.
2001.PubMed/NCBI
|
|
27
|
Judson I, Verweij J, Gelderblom H,
Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan
J, Hohenberger P, et al: European Organisation and Treatment of
Cancer Soft Tissue and Bone Sarcoma Group: Doxorubicin alone versus
intensified doxorubicin plus ifosfamide for first-line treatment of
advanced or metastatic soft-tissue sarcoma: a randomised controlled
phase 3 trial. Lancet Oncol. 15:415–423. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Blay JY, Casali P, Nieto A, Tanović A and
Le Cesne A: Efficacy and safety of trabectedin as an early
treatment for advanced or metastatic liposarcoma and
leiomyosarcoma. Future Oncol. 10:59–68. 2014. View Article : Google Scholar
|
|
29
|
Straussman R, Morikawa T, Shee K,
Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J,
Frederick DT, et al: Tumour micro-environment elicits innate
resistance to RAF inhibitors through HGF secretion. Nature.
487:500–504. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rong G, Kang H, Wang Y, Hai T and Sun H:
Candidate markers that associate with chemotherapy resistance in
breast cancer through the study on Taxotere-induced damage to tumor
microenvironment and gene expression profiling of
carcinoma-associated fibroblasts (CAFs). PLoS One. 8:e709602013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang W, Li Q, Yamada T, Matsumoto K,
Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, Sone S and
Yano S: Crosstalk to stromal fibroblasts induces resistance of lung
cancer to epidermal growth factor receptor tyrosine kinase
inhibitors. Clin Cancer Res. 15:6630–6638. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hwang RF, Moore T, Arumugam T,
Ramachandran V, Amos KD, Rivera A, Ji B, Evans DB and Logsdon CD:
Cancer-associated stromal fibroblasts promote pancreatic tumor
progression. Cancer Res. 68:918–926. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Loeffler M, Krüger JA, Niethammer AG and
Reisfeld RA: Targeting tumor-associated fibroblasts improves cancer
chemotherapy by increasing intratumoral drug uptake. J Clin Invest.
116:1955–1962. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Orimo A, Gupta PB, Sgroi DC,
Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL
and Weinberg RA: Stromal fibroblasts present in invasive human
breast carcinomas promote tumor growth and angiogenesis through
elevated SDF-1/CXCL12 secretion. Cell. 121:335–348. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee YS, Choi I, Ning Y, Kim NY,
Khatchadourian V, Yang D, Chung HK, Choi D, LaBonte MJ, Ladner RD,
et al: Interleukin-8 and its receptor CXCR2 in the tumour
microenvironment promote colon cancer growth, progression and
metastasis. Br J Cancer. 106:1833–1841. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Olumi AF, Grossfeld GD, Hayward SW,
Carroll PR, Tlsty TD and Cunha GR: Carcinoma-associated fibroblasts
direct tumor progression of initiated human prostatic epithelium.
Cancer Res. 59:5002–5011. 1999.PubMed/NCBI
|
|
37
|
Kalluri R and Zeisberg M: Fibroblasts in
cancer. Nat Rev Cancer. 6:392–401. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tarnowski M, Grymula K, Liu R, Tarnowska
J, Drukala J, Ratajczak J, Mitchell RA, Ratajczak MZ and Kucia M:
Macrophage migration inhibitory factor is secreted by
rhabdomyosarcoma cells, modulates tumor metastasis by binding to
CXCR4 and CXCR7 receptors and inhibits recruitment of
cancer-associated fibroblasts. Mol Cancer Res. 8:1328–1343. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mishra P, Banerjee D and Ben-Baruch A:
Chemokines at the crossroads of tumor-fibroblast interactions that
promote malignancy. J Leukoc Biol. 89:31–39. 2011. View Article : Google Scholar
|
|
40
|
Augsten M: Cancer-associated fibroblasts
as another polarized cell type of the tumor microenvironment. Front
Oncol. 4(62)2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sugimoto H, Mundel TM, Kieran MW and
Kalluri R: Identification of fibroblast heterogeneity in the tumor
microenvironment. Cancer Biol Ther. 5:1640–1646. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Harati K, Chromik AM, Bulut D, Goertz O,
Hahn S, Hirsch T, Klein-Hitpass L, Lehnhardt M, Uhl W and Daigeler
A: TRAIL and taurolidine enhance the anticancer activity of
doxorubicin, trabectedin and mafosfamide in HT1080 human
fibrosarcoma cells. Anticancer Res. 32:2967–2984. 2012.PubMed/NCBI
|
|
43
|
Koval OA, Sakaeva GR, Fomin AS, Nushtaeva
AA, Semenov DV, Kuligina EV, Gulyaeva LF, Gerasimov AV and Richter
VA: Sensitivity of endometrial cancer cells from primary human
tumor samples to new potential anticancer peptide lactaptin. J
Cancer Res Ther. 11:345–351. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kakarla S, Song XT and Gottschalk S:
Cancer-associated fibroblasts as targets for immunotherapy.
Immunotherapy. 4:1129–1138. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Underwood TJ, Hayden AL, Derouet M, Garcia
E, Noble F, White MJ, Thirdborough S, Mead A, Clemons N, Mellone M,
et al: Cancer-associated fibroblasts predict poor outcome and
promote periostin-dependent invasion in oesophageal adenocarcinoma.
J Pathol. 235:466–477. 2015. View Article : Google Scholar :
|
|
46
|
Togo S, Polanska UM, Horimoto Y and Orimo
A: Carcinoma-associated fibroblasts are a promising therapeutic
target. Cancers (Basel). 5:149–169. 2013. View Article : Google Scholar
|
